By: Andrea S. Blevins Primeau
Adding isatuximab to carfilzomib and dexamethasone does not improve overall survival in patients with relapsed/refractory multiple myeloma, data from the IKEMA trial suggest.
Andrea S is a writer and producer at various esteemed publications. She covers a range of topics including the coronavirus, social issues, and racial injustice, with a keen interest in the intersection of technology and healthcare, particularly in AI. Her work has been featured in notable outlets such as Cancer Therapy Advisor, The Washington Post, and USA TODAY.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
This information evolves through artificial intelligence and human feedback. Improve this profile .